Cleveland, OH --- May 10, 2005 --- Demand for nanotechnology health care products
in the US is projected to increase nearly 50 percent
per year to $6.5 billion in 2009. Gains will be led
by the introduction of new, improved cancer and central
nervous system therapies based on solubilization
technologies. Diagnostic tests based on nanoarrays
and quantum dots, and imaging agents based on superparamagnetic
iron oxide nanoparticles will also see strong growth.
In spite of progress in introducing new products,
the vast potential of nanotechnology in the health
care field will not be fully realized for at least
a decade as stringent regulatory barriers and technical
complexities delay the commercialization of targeted
drug delivery systems, tissue regenerators and other
breakthrough products. However, by 2020, demand for
nanotechnology health care products is projected
to exceed $100 billion. These and other trends are
presented in Nanotechnology in Health
Care , a new study from The Freedonia
Group, Inc., a Cleveland-based market research firm.
The need for new or improved medicines in several therapeutic areas will lead
to the increasing use of nanotechnology in pharmaceutical applications. Protein-
and peptide-based compounds for cancer, diabetes, infectious diseases and organ
transplant acceptance will account for most growth. Over the long term, pharmaceutical
applications for nanotechnology will extend into most therapeutic classes and
encompass all types of formulations and delivery systems.
Advances in nanotechnology are also creating a wealth of opportunities for
the development of new, improved medical diagnostic products and techniques.
Nanoparticle formulations of superparamagnetic iron oxide, gadolinium, perfluorocarbon
and specialty polymers will broaden in vivo imaging capabilities
by enabling the detection of tumors, plaque, genetic defects and other disease
states at much earlier stages and with lower, safer concentrations of contrast
agents. Several medical supplies and devices will emerge as key applications
for nanotechnology. Nanomaterials are already gaining significant demand as
active ingredients of burn and wound dressings. In the long term, advances
in nanotechnology are expected to lead to the introduction of new, improved
medical supply and device coatings as well as a new, diverse group of medical
implants. The greatest short-term impact of nanotechnology in health care will
be in therapies and diagnostics for cancer and central nervous system disorders.
US NANOTECHNOLOGY HEALTH
CARE PRODUCTS DEMAND
Care Product Demand
|Medical Supplies & Devices
© 2005 by The Freedonia Group, Inc.
Nanotechnology in Health Care (published
05/2005, 355 pages) is available for $4,200 from
The Freedonia Group, Inc., 767 Beta Drive, Cleveland,
OH 44143-2326. For further details, please contact
Corinne Gangloff by phone 440.684.9600, fax 440.646.0484
or e-mail email@example.com.
For more information visit www.freedoniagroup.com
About Freedonia Group:
The Freedonia Group is a leading international business research company, founded
in 1985, that publishes more than 100 industry research studies annually.
Our industry analysis provides an unbiased outlook and a reliable assessment
of an industry and includes product and market forecasts, industry trends,
threats and opportunities, competitive strategies, market share determinations
and company profiles. More than 90% of the industrial companies in the Fortune
500 use Freedonia research to help with their strategic planning.
Copyright © Freedonia Group